Aerami Therapeutics: AER-901 (Inhaled Imatinib) Entering Phase 2 for PAH and PH-ILD
About The Event
Join us for a virtual event with Aerami Therapeutics, featuring Key Opinion Leaders, Vallerie V. McLaughlin, MD (University of Michigan Health) and Oksana A. Shlobin, MD (Inova Fairfax Hospital), who will discuss the current treatment landscape and unmet medical need for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), along with the potential for AER-901 (inhaled imatinib) to provide a valuable and effective solution for both conditions.
Aerami Therapeutics leadership will discuss the company’s innovative “2-in-1” clinical development strategy that doubles the opportunity for patient impact and value creation with a single Phase 2 study. The potential of AER-901 to target low-dose imatinib to the deep lung at therapeutic levels, while minimizing systemic side effects, will also be presented.
A live question and answer session will follow the formal presentations.